Golden
Aperture Venture Partners

Aperture Venture Partners

Aperture Venture Partners is a New York-based venture capital focused on medical device, pharmaceutical, healthcare, and diagnostic sectors.

Company Overview

Aperture Venture Partners is a venture capital group focused primarily on the healthcare and healthy living industries. Initial investment size ranges between $1 million and $5 million and they invest nationally.

History

Aperture invests in consumer goods, medical device, biopharmaceutical, biotechnology, healthcare information technology services and diagnostic sectors. The firm was founded in 2002 by Eric H. Sillman and Paul E. Tierney, Jr.



The firm works exclusively in the healthcare industry. Aperture's principals have been entrepreneurs in the healthcare and investment industries. They have invested more than $1 billion and founded companies that have had combined revenues greater than $2 billion.

Investments

Aperture Venture Partners has raised a total of $49.2M in a single venture fund, Aperture Venture Partners III, L.P. This fund was announced on Dec 31, 2014, and raised a total of $49.2M. The firm has made 34 investments, one of which was on Sep 14, 2018, when they invested $45M in ENDOTRONIX. Aperture Venture Partners has had 15 exits, the most notable ones including Avedro, Inspire Medical Systems, and Aclaris Therapeutics. The firm has $6.4M in revenue annually.

Investment strategy

Aperture Venture Partners, LLC is a venture capital firm specializing in early-stage investments. It seeks to invest in the healthcare and healthy living industries. Within the healthcare industry, the firm invests in biopharmaceutical, biotechnology, healthcare services, healthcare information technology, diagnostics, drug discovery/delivery, and medical devices. Its investments in the healthy living category include companies that offer products or services in the areas of personal care; weight management; complementary and alternative medicines; vitamins, minerals, and supplements; beverages; sporting goods; apparel; retail; and travel. The firm seeks to invest in companies based in the West Coast and North Eastern United States. It typically invests between $1 million and $5 million in its portfolio companies. The firm seeks to be the lead investor and can also co-invest.

Timeline

September 14, 2018

ENDOTRONIX

Series D - ENDOTRONIX

$45M

April 27, 2018

V-Wave

Series C - V-Wave

$70M

April 26, 2018

Cardiac Dimensions

Series B - Cardiac Dimensions

$39M

February 26, 2018

ENDOTRONIX

Series C - ENDOTRONIX

$37.1M

August 23, 2017

Channel Medsystems

Series C - Channel Medsystems

$14.1M

August 7, 2017

Neuros Medical

Series A - Neuros Medical

$20M

July 20, 2017

Trevi Therapeutics

Series C - Trevi Therapeutics

$50.5M

November 1, 2016

Biohaven Pharmaceutical

Venture Round - Biohaven Pharmaceutical

$80M

March 15, 2016

Spirox

Series C - Spirox

$45M

September 9, 2015

Aclaris Therapeutics

Series C - Aclaris Therapeutics

$40M

December 31, 2014

Aperture Venture Partners III, L.P.

$49.2M

Funded Companies

5 Results
Company
Company
Description
Description
Website
Website
Industry
Industry
Location
Location
Funding rounds
Funding rounds
A biopharmaceutical company focused on the discovery of biological products for complicated medical ailments.
A company developing women’s healthcare technologies for endometrial ablation
Ceptaris Therapeutics is a pharmaceutical company developing therapeutics for mycosis fungoides.
A biopharmaceutical company focused on developing treatments for inner and middle ear diseases

People

Name
Role
LinkedIn

Anthony Natale

Managing Partner



Eric H. Sillman

Founder



Paul E. Tierney, Jr.

Co-Founder, Managing Member, Managing Partner and General Partner



Thomas P. Cooper

General Partner



Further reading

Title
Author
Link
Type
Date

Aperture Venture Partners - The Friar Files

Mark Vruno

Web



Aperture Venture Partners Archives - MassDevice

MASSDEVICE

Web



Aperture Venture Partners Raising $100M Fund

Wall Street Journal

Web



Avedro Completes $25 Million Series C Financing SCP Vitalife and Aperture Venture Partners join existing investors







Eric Sillman - Aperture Venture Partners General Partner | Signal



Web



Neuros Medical Closed $20M in Venture Capital Financing |FinSMEs



Web



V-Wave Closes $70M Financing to Support Pivotal Study of its Heart Failure Therapy

V-Wave Ltd.

Web



Documentaries, videos and podcasts

Title
Date
Link

Eric Silman discusses impact investing and the role of accelerators in building the field.

Jul 31, 2012

How to Source Deals: 2nd Annual PE/VC Conference

Jul 24, 2018

Inverted Approach for Capturing Alpha: 2nd Annual PE/VC Conference

Jul 24, 2018

Private Equity in Emerging Markets: Looking Beyond the Internal Rate of Return

November 9, 2010

Sector Specific Due Diligence: 2nd Annual PE/VC Conference



Tony Natale, MD, Aperture Venture Partners, Intro: 2nd Annual PE/VC Conference

Jul 24, 2018

Companies

Company
CEO
Location
Products/Services

Aclarics Therapeutics







Avedro







Axonics







BioHaven Therapeutics



















Cardiocore







Cardiomems

























Concerro







Conor Medsystems







Cortica













Entrigue







Inspire







Interlace







Mako







Neuros Medical







Otonomy







Spirox













Therox







References